TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03117556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Thoracoscopic Splanchnicectomy
Description: BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
Study: NCT01978067

Intervention type: PROCEDURE
Intervention: transvaginal resection of Uterine Scar
Description: Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
Study: NCT01389492

Intervention type: OTHER
Group type: OTHER
Intervention: meat meals
Description: 250 g of meat meal for 4 days

Intervention type: OTHER
Group type: OTHER
Intervention: meat meals
Description: 250 g of meat meal for 4 days

Intervention type: OTHER
Group type: OTHER
Intervention: meat meals
Description: 250 g of meat meal for 4 days
Study: NCT00566852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy
Description: Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiation therapy
Description: Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
Study: NCT01327599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%+Timolol 0.5% ophthalmic solution
Description: Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
Study: NCT04763941

Intervention type: DIAGNOSTIC_TEST
Intervention: CDR assessment face-to-face
Description: The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.
Study: NCT04346329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Treated group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Group
Study: NCT02506634

Intervention type: DRUG
Intervention: Esomeprazole MUPS, 20 mg
Description: According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
Study: NCT04490551

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Risk-based logistic regression model
Description: The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FIT
Description: FIT is a stool-based test that detects human blood in faeces.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FIT
Description: FIT is a stool-based test that detects human blood in faeces.
Study: NCT00207831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur and Uracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur and Uracil
Study: NCT04159740

Intervention type: OTHER
Intervention: Tissue and blood collection
Description: Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.

Intervention type: OTHER
Intervention: Tissue and blood collection
Description: Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
Study: NCT02860650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Filo
Description: Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Filo
Description: Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Filo
Description: Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Filo
Description: Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection of 0.9 percent saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection of 0.9 percent saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection of 0.9 percent saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection of 0.9 percent saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection of 0.9 percent saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.
Study: NCT03690102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-CPR
Description: Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-CPR
Description: Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERC standardized BLS course
Description: Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERC standardized BLS course
Description: Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
Study: NCT04456062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Description: Caring Contacts are brief email communications sent to the patient post-discharge. They convey messages of hope, support, promote a sense of belonging, and provide information on resources for care. They are not written uniquely for each patient but are purposefully crafted to intervene on those specific vulnerabilities that form the core of many patients' experiences with intense emotional distress and suicidal thoughts.
Study: NCT02630992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate potassium
Study: NCT03401502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Oral, b.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral, b.i.d
Study: NCT00943930

Intervention type: DRUG
Intervention: THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC
Description: During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
Study: NCT02934165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Safety 123
Description: Theoretically-based injury prevention videos for families

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AAP TIPP sheets
Description: American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
Study: NCT01493973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03864419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study: NCT02518763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3, 100 000 IU weekly, 4 times

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 OH vitamin D serum concentration measurements
Study: NCT03243357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TF Adaptive (First Apical Binding File)
Description: Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file.
Study: NCT03864419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT03243357

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TF Adaptive (Control)
Description: Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions.
Study: NCT00604630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin alfa
Description: 40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
Study: NCT03864302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Motor imagery (MI) is a psychological technique for improvement of motor skills.(24) MI skill training (MIST) has been used and explored in several disciplines including Sports, Music, Education, Psychology and Medicine.(18) The literature has found positive effects on performances in professional athletes but also on rehabilitation of stroke patients.(25,26) MI is a cognitive imagery of a physical performance, e.g. a high jumper imagine a high jump, prior to performance. MI is not as effective as physical practice, but more effective compared to no training.(27) Further, MI combined with physical practice has been found to be more effective in skill performance in sports compared to physical practice alone.(18) MIST has shown promising results on surgical performances in flexible cystoscopy performed by doctors.(28)
Study: NCT05622565

Intervention type: DIAGNOSTIC_TEST
Intervention: Various modalities of ocular fundus imaging
Description: Through various modalities of ocular fundus imaging, combining with clinical data and the experience of clinicians to diagnose different fundus diseases.
Study: NCT03864419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT03081650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo Humidifier
Study: NCT03567876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
Study: NCT02023996

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-trastuzumab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET imaging
Study: NCT04674722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 99mTc-NM-02
Description: A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 188Re-NM-02
Description: A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy
Study: NCT03864419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT02313584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabigatran

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01636986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily wear, daily disposable use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Description: Hydrogel contact lenses for daily wear, daily disposable use
Study: NCT03864419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT01009814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068 will be administered as a tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068 will be administered as a tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068 will be administered as a tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068 will be administered as a tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068 will be administered as a tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as a capsule.
Study: NCT03095664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: A behavior change program with 4 monthly 90-min sessions about healthy eating and physical activity.
Study: NCT01242605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
Study: NCT03793608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
Study: NCT03658044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in the internet forum
Description: Active participation in the forum with encouragement to participate on a weekly basis
Study: NCT01242605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m\*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin: 25 mg/m\*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
Study: NCT03325595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEF0117
Description: 0.2, 0.6, 2, or 6mg of AEF0117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule placebo
Study: NCT03971448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LPWB
Description: The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKWC
Description: If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
Study: NCT01195805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 1 tablet twice a day for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice a day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: 1 tablet twice a day for 28 days
Study: NCT02498093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal strength training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Study: NCT00286429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and insulin
Description: Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and insulin
Description: Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
Study: NCT02956317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STP705
Description: The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STP705
Description: The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT02906527

Intervention type: DRUG
Intervention: Non-exposed group
Description: Non-exposed group / Patients receiving VKA

Intervention type: DRUG
Intervention: Exposed group
Description: Exposed group / Patients receiving DOAC
Study: NCT02425774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus stimulation
Study: NCT02956317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal Saline